Table 4.

Diagnostic efficacy of FPR and GPR used alone or in combination in differentiating patients with AFP-NHCC from other patients

	Cutoff	Sensitivity (%)	Specificity (%)	PLR	NLR	PPV (%)	NPV (%)	AUC (95% CI)	p
FPRa	11.57	86.67	88.44	7.50	0.15	87.2	88.0	0.935 (0.905–0.957)	< 0.001
GPRa	0.21	67.78	94.47	12.26	0.34	91.7	76.4	0.884 (0.848–0.915)	< 0.001
FPRa + GPRa	0.44	91.11	96.48	25.90	0.09	95.9	92.3	0.977 (0.957–0.990)	< 0.001
FPRb	16.70	46.11	94.02	7.71	0.57	88.3	64.1	0.696 (0.646–0.743)	< 0.001
GPRb	0.23	64.44	61.96	1.69	0.57	62.4	64.0	0.677 (0.626–0.725)	< 0.001
FPRb + GPRb	0.55	67.22	74.46	2.63	0.44	72.0	69.9	0.745 (0.697–0.789)	< 0.001
FPRc	20.72	26.11	93.38	3.94	0.79	82.5	51.5	0.623 (0.568–0.675)	< 0.001
GPRc	0.20	68.89	43.71	1.22	0.71	59.3	54.1	0.617 (0.563–0.670)	< 0.001
FPRc + GPRc	0.42	46.11	81.46	2.49	0.66	74.8	55.9	0.666 (0.612–0.716)	< 0.001
FPRd	11.30	80.00	86.43	5.90	0.23	54.2	95.6	0.914 (0.871–0.946)	< 0.001
GPRd	0.19	60.00	89.95	5.97	0.44	54.5	91.8	0.801 (0.745–0.850)	< 0.001
FPRd + GPRd	0.15	87.50	86.93	6.70	0.14	57.4	97.2	0.943 (0.906–0.969)	< 0.001
FPRe	11.26	86.11	85.93	6.12	0.16	76.9	91.9	0.916 (0.879–0.944)	< 0.001
GPRe	0.21	66.67	94.47	12.06	0.35	86.7	83.9	0.859 (0.814–0.896)	< 0.001
FPRe + GPRe	0.16	89.81	96.48	25.53	0.11	93.3	94.6	0.971 (0.945–0.987)	< 0.001

FPR fibrinogen to prealbumin ratio, GPR gamma-glutamyl transpeptidase to platelet ratio, PLR positive likelihood ratio, NLR negative likelihood ratio, PPV positive predictive value, NPV negative predictive value, CI confidence interval, AUC area under curve, AFP-NHCC alpha-fetoprotein-negative hepatocellular carcinoma, AFP alpha-fetoprotein, CH chronic hepatitis, LC liver cirrhosis, BCLC Barcelona Clinic Liver Cancer

^aAFP-NHCC patients vs healthy controls

^bAFP-NHCC patients vs AFP-negative CH patients

^cAFP-NHCC patients vs AFP-negative LC patients

^dAFP-NHCC patients with tumor size < 3 cm vs healthy controls

^eAFP-NHCC patients with BCLC-A stage vs healthy controls